Journals / Journal of Health Sciences and Medicine / 2021 / Cilt: 4 - Sayı: 6

The spectrum of underlying diseases in children with autoimmune hemolytic anemia

Pages
772–778
Publication Date
2021-09-24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found that there were underlying risk factors in 36 patients with secondary AIHA, as immunodeficiency and autoimmune disorders being the most common risk factors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Autoimmune hemolytic anemia (AIHA) is characterized by the production of antibodies directed against red blood cells.
📊
Key Findings & Data:Material and Method: In a retrospectively manner, we consecutively recrutied 62 children (aged 1 month-18 years) with AIHA who had been followed in Erciyes University Child Hospital between January, 2000 and November, 2017.
💡
Conclusion & Impact:It was found that there were underlying risk factors in 36 patients with secondary AIHA, as immunodeficiency and autoimmune disorders being the most common risk factors.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Autoimmune hemolytic anemia · children · immunodeficiency

Abstract

Aim: Autoimmune hemolytic anemia (AIHA) is characterized by the production of antibodies directed against red blood cells. We aimed to describe the clinical presentation, hematologic and biochemical profiles, treatment modalities, underlying diseases and outcomes in children suffering from AIHA. Material and Method: In a retrospectively manner, we consecutively recrutied 62 children (aged 1 month-18 years) with AIHA who had been followed in Erciyes University Child Hospital between January, 2000 and November, 2017. Results: The mean age at time of diagnosis was 61.9±51.9 months (range:1-192) in 62 children including 28 girls and 34 boys. The most common complaints included fatigue and fever while the most common findings were jaundice and hepatosplenomegaly. In 22 children (35.4%), there was a comorbid, active, non-specific infection (upper respiratory tract infection, lower respiratory tract infection, diarrhea, urinary tract infection). At time of diagnosis, mean hemoglobin (Hb) level was 6.9±2.5 g/dL (range: 5-9). The glucocorticoid therapy was given in majority of the patients while no medical treatment was given to 4 patients. Of the patients with primary AIHA, 6 patients were unresponsive to the treatment while one patient responded partially. It was found that there were underlying risk factors in 36 patients with secondary AIHA, as immunodeficiency and autoimmune disorders being the most common risk factors. Conclusion: The immunodeficiencies were highly prevalent in children included. By advance of whole exome sequencing technology, we believe that primary immunodeficiencies was the most common underlying disease in our study detected quite high in presented children.

🔖

Cite This Article

ÖZCAN, A., CANSEVER, M., YILMAZ, E., ÜNAL, E., KARAKÜKÇÜ, M., PATIROĞLU, T. (2021). The spectrum of underlying diseases in children with autoimmune hemolytic anemia. Journal of Health Sciences and Medicine, Cilt: 4 - Sayı: 6, 772–778. https://ajindex.com/articles/776711

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Liebman HA, WeitzIC. Autoimmune hemolytic anemia. Med Clin North Am 2017; 101: 351-9.
  2. Aladjidi N, Jutand MA, Beaubois C, et al. Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatr Blood Cancer 2017; 64: 12. Sarper N, Çakı Kılıç S, Zengin E, et al. Management of autoimmune hemolytic anemia in children and adolescents: A single center experience. Turk J Haematol 2011; 28: 198-205.
  3. Vagace JM, Bajo R, Gervasini G. Diagnostic and therapeutic challenges of primary autoimmune haemolytic anaemia in children. Arch Dis Child 2014; 99: 668-73.
  4. Carson JL, Grossman BJ, Kleinman S, et al. Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med. 2012; 157: 49-58.
  5. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood.2017; 129: 2971-9.
  6. Ladogana S, Maruzzi M, Samperi P, et al. Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association. Blood Transfus 2017;15: 259–67.
  7. Ozcan A, Canpolat M, Doganay S, et al. Cerebral sinus venous thrombosis and prothrombotic risk factors in children: a single-center experience from Turkey. J Pediatr Hematol Oncol 2018; 40: 369-72.
  8. Yaralı N, Bilir ÖA, Erdem AY, et al. Clinical features and treatment of primary autoimmune hemolytic anemia in childhood. Transfus Apher Sci 2018; 57: 665-8. 10.Naithani R, Agrawal N, Mahapatra M, et al. Autoimmune haemolytic anemia in children. Pediatr Hematol Oncol 2007; 24: 309-15.
  9. Aladjidi N, Leverger G, Leblanc T, et al. Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE). New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica 2011; 96: 655-63.
  10. Sankaran J, Rodriguez V, Jacob EK, et al. Autoimmune hemolytic anemia in children: mayo clinic experience. J Pediatr Hematol Oncol 2016; 38: 120-4.
  11. Berentsen S, Sundic T. Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. Biomed Res Int 2015; 2015: 363278. Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv 2019; 3: 1897-906.
  12. Apak H, Karaman S, Doğan Y,etal. Varicella-induced haemolytic anemia with hepatitis. Ann Hematol 2006; 85: 64-5.
  13. Zhang QL, J